THER Stock Overview
A commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Theralink Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0035 |
| 52 Week Low | US$0.0001 |
| Beta | 19.71 |
| 11 Month Change | -85.71% |
| 3 Month Change | -90.91% |
| 1 Year Change | -95.00% |
| 33 Year Change | -99.99% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| THER | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | -0.2% |
| 1Y | -95.0% | 10.7% | 22.9% |
Return vs Industry: THER underperformed the US Biotechs industry which returned 10.7% over the past year.
Return vs Market: THER underperformed the US Market which returned 22.9% over the past year.
Price Volatility
| THER volatility | |
|---|---|
| THER Average Weekly Movement | 40.0% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: THER's share price has been volatile over the past 3 months.
Volatility Over Time: THER's weekly volatility has increased from 33% to 40% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 16 | n/a | www.theralink.com |
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States. The company offers patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It also provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments.
Theralink Technologies, Inc. Fundamentals Summary
| THER fundamental statistics | |
|---|---|
| Market cap | US$615.15k |
| Earnings (TTM) | -US$13.50m |
| Revenue (TTM) | US$635.45k |
1.0x
P/S Ratio0.0x
P/E RatioIs THER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THER income statement (TTM) | |
|---|---|
| Revenue | US$635.45k |
| Cost of Revenue | US$245.25k |
| Gross Profit | US$390.20k |
| Other Expenses | US$13.89m |
| Earnings | -US$13.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0022 |
| Gross Margin | 61.41% |
| Net Profit Margin | -2,124.13% |
| Debt/Equity Ratio | -39.5% |
How did THER perform over the long term?
See historical performance and comparison